Safety and Efficacy of Subretinal AAV-CRISPR/Cas9 Gene Editing for Rhodopsin-Mutant Retinitis Pigmentosa: A Phase I/IIa Dose-Escalation Triall. Sriwijaya Journal of Ophthalmology, v. 8, n. 2, p. 478–485, 19 Jun.2026.